CY2022024I1 - Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv - Google Patents

Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv

Info

Publication number: CY2022024I1
Authority: CY; Cyprus
Prior art keywords: pyrimidines; hiv; multiplication; inhibit
Prior art date: 2001-08-13

Application number

CY2022024C

Other languages

English (en)

Other versions

CY2022024I2 (el

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-13

Filing date

2022-08-01

Publication date

2023-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2022024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A20-cv-00189 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.

2022-08-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2023-01-05 Publication of CY2022024I2 publication Critical patent/CY2022024I2/el

2023-01-05 Publication of CY2022024I1 publication Critical patent/CY2022024I1/el

Links

150000003230 pyrimidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CY2022024C 2001-08-13 2022-08-01 Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv CY2022024I1 (el)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP01203090		2001-08-13
EP02077748		2002-06-10
EP02764839A EP1419152B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
PCT/EP2002/008953 WO2003016306A1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
EP10178189.6A EP2298761B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives

Publications (2)

Publication Number	Publication Date
CY2022024I2 CY2022024I2 (el)	2023-01-05
CY2022024I1 true CY2022024I1 (el)	2023-01-05

Family

ID=26076978

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CY20111101014T CY1112331T1 (el)	2001-08-13	2011-10-26	Παραγωγα πυριμιδινης που αναστελλουν τον hiv
CY2012012C CY2012012I1 (el)	2001-08-13	2012-05-18	Παραγωγα πυριμιδινης που αναστελλουν τον hiv
CY2012013C CY2012013I2 (el)	2001-08-13	2012-05-25	Παραγωγα πυριμιδινης που αναστελλουν τον hiv
CY2022024C CY2022024I1 (el)	2001-08-13	2022-08-01	Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
CY20111101014T CY1112331T1 (el)	2001-08-13	2011-10-26	Παραγωγα πυριμιδινης που αναστελλουν τον hiv
CY2012012C CY2012012I1 (el)	2001-08-13	2012-05-18	Παραγωγα πυριμιδινης που αναστελλουν τον hiv
CY2012013C CY2012013I2 (el)	2001-08-13	2012-05-25	Παραγωγα πυριμιδινης που αναστελλουν τον hiv

Country Status (38)

Country	Link
US (8)	US7125879B2 (el)
EP (3)	EP3808743B1 (el)
JP (4)	JP2005507380A (el)
KR (2)	KR100969273B1 (el)
CN (2)	CN101816658B (el)
AP (1)	AP1610A (el)
AR (1)	AR036387A1 (el)
AT (1)	ATE517891T1 (el)
AU (1)	AU2002329238C1 (el)
BE (3)	BE2012C020I2 (el)
BR (3)	BRPI0211909B8 (el)
CA (1)	CA2452217C (el)
CY (4)	CY1112331T1 (el)
DE (1)	DE122012000038I1 (el)
DK (2)	DK3808743T3 (el)
EA (1)	EA006656B1 (el)
EG (1)	EG24684A (el)
ES (3)	ES2923581T3 (el)
FR (3)	FR12C0035I2 (el)
HK (2)	HK1070066A1 (el)
HR (3)	HRP20192051B1 (el)
HU (5)	HU230192B1 (el)
IL (2)	IL160328A0 (el)
JO (1)	JO3429B1 (el)
LT (2)	LT3808743T (el)
LU (2)	LU92001I2 (el)
MX (1)	MXPA04001401A (el)
MY (1)	MY189572A (el)
NO (3)	NO327639B1 (el)
NZ (1)	NZ530951A (el)
OA (1)	OA12652A (el)
PA (1)	PA8552901A1 (el)
PL (2)	PL402388A1 (el)
PT (1)	PT1419152E (el)
SI (2)	SI1419152T1 (el)
UA (1)	UA78221C2 (el)
WO (1)	WO2003016306A1 (el)
ZA (1)	ZA200401159B (el)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ATE424395T1 (de)	2002-03-13	2009-03-15	Janssen Pharmaceutica Nv	Aminoderivate als histone-deacetylase-inhibitoren
AR039540A1 (es) *	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
US7517886B2 (en)	2002-07-29	2009-04-14	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN102225902B (zh)	2002-08-09	2013-04-24	詹森药业有限公司	制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
RS20050363A (en) *	2002-11-28	2007-11-15	Schering Aktiengesellschaft,	Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
CN102503903A (zh) *	2003-02-07	2012-06-20	詹森药业有限公司	抑制hiv的1,2,4-三嗪
US20070021449A1 (en) *	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
CL2004000303A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BRPI0412734A (pt)	2003-07-17	2006-09-26	Tibotec Pharm Ltd	processo para preparação de partìculas que contêm um antiviral
DK1656372T3 (da)	2003-07-30	2013-07-01	Rigel Pharmaceuticals Inc	2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
AU2004264382A1 (en) *	2003-08-15	2005-02-24	Irm Llc	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) *	2003-09-03	2012-06-11	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
ATE500254T1 (de) *	2003-09-25	2011-03-15	Janssen Pharmaceutica Nv	Die replikation von hiv hemmende purinderivate
MX2007001120A (es)	2004-07-28	2007-03-15	Janssen Pharmaceutica Nv	Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa.
WO2006015985A1 (en)	2004-08-10	2006-02-16	Janssen Pharmaceutica N.V.	Hiv inhibiting 1,2,4-triazin-6-one derivatives
NZ581376A (en)	2004-08-25	2011-05-27	Ardea Biosciences Inc	Intermediates useful in the synthesis of S-triazolyl alpha-mercaptoacetanildes for inhibition of HIV reverse transcriptase
WO2007050087A1 (en)	2004-08-25	2007-05-03	Ardea Biosciences, Inc.	N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
US20090215804A1 (en) *	2004-09-02	2009-08-27	Paul Theodoor Agnes Stevens	Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
PL1632232T6 (pl) *	2004-09-02	2022-06-27	Janssen Pharmaceutica Nv	Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CA2577273C (en) *	2004-09-02	2013-11-19	Janssen Pharmaceutica N.V.	Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EP1632232B3 (en) *	2004-09-02	2022-03-30	Janssen Pharmaceutica NV	Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
AP2296A (en) *	2004-09-02	2011-10-31	Janssen Pharmaceutica Nv	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
MX2007003318A (es)	2004-09-20	2007-05-18	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
TW200626155A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
WO2006034441A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051093A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
JP5043668B2 (ja)	2004-09-20	2012-10-10	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
TW200626572A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
WO2006034440A2 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
RU2403244C2 (ru) *	2004-09-30	2010-11-10	Тиботек Фармасьютикалз Лтд.	Вич-ингибирующие 5-карбо- или гетероциклические замещенные пиримидины
TW200626574A (en)	2004-09-30	2006-08-01	Tibotec Pharm Ltd	HIV inhibiting 5-heterocyclyl pyrimidines
CN101027288B (zh) *	2004-09-30	2013-04-17	泰博特克药品有限公司	抑制hiv的5-取代嘧啶
SI1814878T1 (sl)	2004-11-24	2012-06-29	Rigel Pharmaceuticals Inc	Spojine spiro-2,4-pirimidindiamina in njihova uporaba
PL1856135T3 (pl)	2005-01-19	2010-05-31	Rigel Pharmaceuticals Inc	Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
ES2548729T3 (es)	2005-03-31	2015-10-20	Santen Pharmaceutical Co., Ltd.	Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
TW201414495A (zh)	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
EP1877411B9 (en)	2005-05-05	2012-08-29	Ardea Biosciences, Inc.	Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
US8101752B2 (en) *	2005-05-26	2012-01-24	Tibotec Pharmaceuticals Ltd.	Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
MX2007015216A (es)	2005-06-03	2008-02-22	Xenon Pharmaceuticals Inc	Derivados de aminotiazol y sus usos como agentes terapeuticos.
JP5225079B2 (ja)	2005-06-08	2013-07-03	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2007082874A1 (en)	2006-01-19	2007-07-26	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
BRPI0707179A2 (pt) *	2006-01-20	2011-04-26	Tibotec Pharm Ltd	tratamento de longo termo de infecção por hiv
CA2645958C (en)	2006-03-30	2014-11-04	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-amido substituted pyrimidines
US8163745B2 (en)	2006-03-30	2012-04-24	Tibotec Pharmaceuticals Ltd.	HIV inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
AU2014200819B2 (en) *	2006-06-23	2016-05-26	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
AU2016219555B2 (en) *	2006-06-23	2017-08-10	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
PE20080210A1 (es) *	2006-06-23	2008-04-11	Tibotec Pharm Ltd	Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278)
WO2008058285A2 (en)	2006-11-09	2008-05-15	Ardea Biosciences, Inc.	4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
KR101364277B1 (ko)	2006-12-08	2014-02-21	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물
CN101553483B (zh) *	2006-12-13	2013-04-17	弗·哈夫曼-拉罗切有限公司	作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
US9006243B2 (en)	2006-12-29	2015-04-14	Janssen R&D Ireland	HIV inhibiting 6-substituted pyrimidines
EP2114902B1 (en)	2006-12-29	2014-09-17	Janssen R&D Ireland	Hiv inhibiting 5,6-substituted pyrimidines
WO2008094992A2 (en)	2007-01-31	2008-08-07	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as kinase inhibitors
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
ES2593486T3 (es)	2007-04-18	2016-12-09	Pfizer Products Inc.	Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
ES2542153T3 (es)	2007-05-30	2015-07-31	F. Hoffmann-La Roche Ag	Inhibidores no nucleósidos de la transcriptasa inversa
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
RU2498979C2 (ru) *	2007-07-12	2013-11-20	Тиботек Фармасьютикалз	Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CN101407476B (zh) *	2007-10-12	2012-07-18	中国人民解放军军事医学科学院毒物药物研究所	作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
BRPI0819847B1 (pt)	2007-11-27	2022-01-11	Ardea Biosciences, Inc	Compostos e composições
WO2009079412A2 (en)	2007-12-14	2009-06-25	Ardea Biosciences Inc.	Reverse transcriptase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en)	2008-06-27	2016-01-28	Celgene Avilomics Res Inc	Heteroaryl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010011756A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
AU2009274023A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009279611A1 (en)	2008-08-06	2010-02-11	Vertex Pharmaceuticals Incorporated	Aminopyridine kinase inhibitors
CN101717364B (zh) *	2008-10-09	2014-08-13	中国人民解放军军事医学科学院毒物药物研究所	作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
WO2010040275A1 (zh) *	2008-10-09	2010-04-15	中国人民解放军军事医学科学院毒物药物研究所	作为非核苷类hiv逆转录酶抑制剂的2-（4-取代苯胺基）多取代吡啶类化合物、其制备方法及用途
EP2181991A1 (en)	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Novel salts of sunitinib
EP2186809A1 (en) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	New crystal form of sunitinib malate
MY160360A (en)	2008-12-24	2017-02-28	Janssen Sciences Ireland Uc	Implantable devices for treating hiv
CA2760794C (en)	2009-05-05	2017-07-25	Dana Farber Cancer Institute	Egfr inhibitors and methods of treating disorders
EP2427464A1 (en)	2009-05-06	2012-03-14	Vertex Pharmaceuticals Incorporated	Pyrazolopyridines
JP2013518114A (ja)	2010-01-27	2013-05-20	バーテックスファーマシューティカルズインコーポレイテッド	ピラゾロピリミジンキナーゼ阻害剤
JP5769733B2 (ja)	2010-01-27	2015-08-26	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	ピラゾロピリジンキナーゼ阻害剤
EA037601B1 (ru)	2010-01-27	2021-04-20	Вайв Хелткер Компани	Комбинация для лечения вич-инфекции
MX2012008641A (es)	2010-01-27	2012-11-23	Vertex Pharma	Inhibidores de cinasas de pirazolopirazinas.
US20140018379A1 (en) *	2010-02-18	2014-01-16	Concert Pharmaceuticals Inc.	Pyrimidine derivatives
US8367315B2 (en) *	2010-03-05	2013-02-05	Adan Rios	Inactivation of reverse transcriptases by azido-diarylpyrimidines
BR112013003388A2 (pt)	2010-08-10	2016-07-12	Celgene Avilomics Res Inc	sal de besilato de um inibidor de btk
JP5956999B2 (ja)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
MY181898A (en)	2010-11-01	2021-01-12	Celgene Car Llc	Heterocyclic compounds and uses thereof
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
JP5957003B2 (ja)	2010-11-10	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	変異体選択的ｅｇｆｒ阻害剤およびその使用
TWI556840B (zh)	2010-11-19	2016-11-11	吉李德科學股份有限公司	治療用組成物
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
WO2012147091A2 (en)	2011-04-25	2012-11-01	Hetero Research Foundation	Process for rilpivirine
AU2012302144B2 (en)	2011-08-30	2017-06-15	Chdi Foundation, Inc.	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755959B1 (en)	2011-09-16	2018-05-16	Hetero Research Foundation	Rilpivirine hydrochloride
TW201325593A (zh)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
EP2604593A1 (en)	2011-12-14	2013-06-19	Sandoz AG	Polymorph of Rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en)	2012-02-20	2013-08-21	Sandoz AG	Novel crystalline form of rilpivirine hydrochloride
WO2013087794A1 (en)	2011-12-14	2013-06-20	Sandoz Ag	Polymorph of rilpivirine hydrochloride and its use as antiviral
KR102090453B1 (ko)	2012-03-15	2020-03-19	셀젠 카르 엘엘씨	상피 성장 인자 수용체 키나제 억제제의 염
MY169233A (en)	2012-03-15	2019-03-19	Celgene Car Llc	Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013153161A2 (en)	2012-04-11	2013-10-17	Sandoz Ag	Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en)	2012-04-11	2013-10-17	Sandoz Ag	Polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) *	2012-06-01	2013-12-05	Laurus Labs Private Limited	Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
US9139535B2 (en) *	2012-07-12	2015-09-22	Hetero Research Foundation	Process for rilpivirine using novel intermediate
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
WO2014100748A1 (en)	2012-12-21	2014-06-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US9145387B2 (en)	2013-02-08	2015-09-29	Celgene Avilomics Research, Inc.	ERK inhibitors and uses thereof
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
BR112017000922A2 (pt) *	2014-07-17	2018-01-16	Chdi Foundation, Inc.	métodos e composições para tratar distúrbios relacionados ao hiv
DK3179858T3 (da)	2014-08-13	2019-07-22	Celgene Car Llc	Forme og sammensætninger af en ERK-inhibitor
PE20170691A1 (es)	2014-09-26	2017-06-13	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones farmaceuticas de accion prolongada
CZ201532A3 (cs)	2015-01-21	2015-02-25	Zentiva, K.S.	Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) *	2015-06-08	2015-09-23	山东大学	一种噻吩并嘧啶类衍生物及其制备方法和应用
PL3607939T3 (pl)	2015-06-30	2022-11-07	Gilead Sciences, Inc.	Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę
CZ2015579A3 (cs)	2015-08-27	2017-03-08	Zentiva, K.S.	Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) *	2016-07-04	2018-08-21	宜昌人福药业有限责任公司	一种有效去除利匹韦林异构体的方法
WO2018077815A1 (en)	2016-10-24	2018-05-03	Janssen Sciences Ireland Uc	Dispersible compositions
CN106749203B (zh) *	2016-11-28	2020-04-10	洛阳聚慧医药科技有限公司	一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) *	2016-12-08	2018-12-25	西北师范大学	一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) *	2017-02-27	2019-08-16	武汉工程大学	二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
AU2019344899A1 (en)	2018-09-18	2021-04-15	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as Src homology-2 phosphatase inhibitors
CN109293581B (zh) *	2018-09-21	2020-03-27	宜昌人福药业有限责任公司	一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
US20210380540A1 (en)	2018-10-25	2021-12-09	Minakem	Process for the preparation of rilpivirine
WO2021001508A1 (en) *	2019-07-03	2021-01-07	Janssen Sciences Ireland Unlimited Company	Methods of treating hiv in pediatric patients with rilpivirine
CN110526873B (zh) *	2019-08-15	2022-09-16	复旦大学	氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
JP2023503403A (ja)	2019-11-29	2023-01-30	シピオライフサイエンシズリミテッド	リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用
CN111004215B (zh) *	2019-12-22	2022-08-09	华北理工大学	2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) *	2020-02-21	2021-03-16	山东大学	噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
WO2022000019A1 (en) *	2020-06-30	2022-01-06	University Of South Australia	New therapeutic use of rilpivirine
CN112028836B (zh) *	2020-09-09	2021-12-07	山东大学	一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) *	2020-09-09	2024-01-30	瑞阳制药股份有限公司	一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh)	2020-11-17	2022-09-01	愛爾蘭商健生科學愛爾蘭無限公司	Hiv感染之治療或預防
CN112546969B (zh) *	2020-12-07	2022-12-23	安徽贝克制药股份有限公司	催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) *	2021-01-13	2021-05-11	安徽贝克联合制药有限公司	用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) *	2021-03-08	2021-07-13	复旦大学	一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) *	2021-05-06	2021-10-01	复旦大学	含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) *	2021-09-03	2021-12-28	复旦大学	一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
EP4433026A1 (en)	2021-11-17	2024-09-25	Janssen Sciences Ireland Unlimited Company	Dissolution test
WO2023203258A1 (en)	2022-04-22	2023-10-26	Janssen Sciences Ireland Unlimited Company	Liquid compositions
WO2023203257A1 (en)	2022-04-22	2023-10-26	Janssen Sciences Ireland Unlimited Company	Freeze dried compositions
TW202408527A (zh)	2022-05-17	2024-03-01	愛爾蘭商健生科學愛爾蘭無限公司	治療或預防hiv感染(二)
TW202408526A (zh)	2022-05-17	2024-03-01	愛爾蘭商健生科學愛爾蘭無限公司	治療或預防hiv感染(一)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3953398A (en) *	1970-07-20	1976-04-27	The Goodyear Tire & Rubber Company	Age resistant polymeric compositions
EP0002341B1 (en) *	1977-11-28	1982-01-20	Barry Boettcher	Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS63159316A (ja) *	1977-11-28	1988-07-02	アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド	中性銅結合体を含む抗炎症組成物
JPS5879920A (ja) *	1981-11-09	1983-05-13	Kanegafuchi Chem Ind Co Ltd	血小板凝集阻害剤
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
CZ154398A3 (cs)	1995-11-23	1998-08-12	Janssen Pharmaceutica N.V.	Pevné směsi cyklodextrinů připravené vytlačováním taveniny
TW429256B (en)	1995-12-27	2001-04-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
JP3990808B2 (ja) *	1998-03-26	2007-10-17	Ｔｄｋ株式会社	非水電解質電池用電極の製造方法
DE69943247D1 (de) *	1998-03-27	2011-04-14	Janssen Pharmaceutica Nv	HIV hemmende Pyrimidin Derivate
EP0945447A1 (en) *	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
KR100699514B1 (ko)	1998-03-27	2007-03-26	얀센 파마슈티카 엔.브이.	Ｈｉｖ를 억제하는 피리미딘 유도체
JP2000035628A (ja) *	1998-07-16	2000-02-02	Konica Corp	ハロゲン化銀写真感光材料
EP1107957B1 (en) *	1998-08-29	2006-10-18	AstraZeneca AB	Pyrimidine compounds
EA004049B1 (ru) *	1998-11-10	2003-12-25	Янссен Фармацевтика Н.В.	Пиримидины, ингибирующие репликацию вич
SK12582001A3 (sk)	1999-03-09	2002-02-05	Pharmacia & Upjohn Company	4-Oxo-4,7-dihydro-tieno[2,3-b] pyridín-5-karboxamidy ako antivírusové prostriedky, spôsob ich prípravy, medziprodukty a farmaceutická kompozícia
KR100722344B1 (ko)	1999-04-15	2007-05-29	브리스톨-마이어스스퀴브컴파니	환형 단백질 티로신 키나제 억제제
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
EE04991B1 (et) *	1999-09-24	2008-04-15	Janssen Pharmaceutica N.V.	Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
US20030004174A9 (en)	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
CA2407754C (en)	2000-05-08	2009-09-15	Janssen Pharmaceutica N.V.	Prodrugs of hiv replication inhibiting pyrimidines
JP5230050B2 (ja)	2000-05-08	2013-07-10	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖ複製阻害剤
US6596729B2 (en)	2000-07-20	2003-07-22	Bristol-Myers Squibb Company	Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CA2439820A1 (en) *	2001-03-02	2002-09-12	Smithkline Beecham Corporation	Benzophenones as inhibitors of reverse transcriptase
JP4160401B2 (ja) *	2001-03-29	2008-10-01	バーテックスファーマシューティカルズインコーポレイテッド	Ｃ−ｊｕｎｎ末端キナーゼ（ｊｎｋ）および他のタンパク質キナーゼのインヒビター
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002329842B2 (en) *	2001-08-29	2006-09-14	Umd, Inc.	Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
KR20040111466A (ko) *	2002-05-03	2004-12-31	얀센 파마슈티카 엔.브이.	폴리머성 마이크로에멀젼
CN102225902B (zh) *	2002-08-09	2013-04-24	詹森药业有限公司	制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) *	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
US9226970B2 (en) *	2010-02-22	2016-01-05	Nektar Therapeutics	Oligomer modified diaromatic substituted compounds

2002
- 2002-07-16 JO JOP/2002/0074A patent/JO3429B1/ar active
- 2002-08-09 HU HU0401346A patent/HU230192B1/hu active Protection Beyond IP Right Term
- 2002-08-09 PL PL402388A patent/PL402388A1/pl unknown
- 2002-08-09 AP APAP/P/2004/002993A patent/AP1610A/en active
- 2002-08-09 DK DK20165399.5T patent/DK3808743T3/da active
- 2002-08-09 CN CN200910145401.5A patent/CN101816658B/zh not_active Expired - Lifetime
- 2002-08-09 ES ES20165399T patent/ES2923581T3/es not_active Expired - Lifetime
- 2002-08-09 NZ NZ530951A patent/NZ530951A/en not_active IP Right Cessation
- 2002-08-09 PT PT02764839T patent/PT1419152E/pt unknown
- 2002-08-09 WO PCT/EP2002/008953 patent/WO2003016306A1/en active Application Filing
- 2002-08-09 EA EA200400304A patent/EA006656B1/ru active IP Right Maintenance
- 2002-08-09 AT AT02764839T patent/ATE517891T1/de active
- 2002-08-09 EP EP20165399.5A patent/EP3808743B1/en not_active Expired - Lifetime
- 2002-08-09 BR BRPI0211909-9 patent/BRPI0211909B8/pt active IP Right Grant
- 2002-08-09 CA CA002452217A patent/CA2452217C/en not_active Expired - Lifetime
- 2002-08-09 KR KR1020077022611A patent/KR100969273B1/ko active Protection Beyond IP Right Term
- 2002-08-09 MY MYPI20071005A patent/MY189572A/en unknown
- 2002-08-09 EP EP10178189.6A patent/EP2298761B1/en not_active Expired - Lifetime
- 2002-08-09 SI SI200230963T patent/SI1419152T1/sl unknown
- 2002-08-09 ES ES10178189T patent/ES2799408T3/es not_active Expired - Lifetime
- 2002-08-09 BR BR122015032641-9A patent/BR122015032641B1/pt not_active IP Right Cessation
- 2002-08-09 HR HRP20192051AA patent/HRP20192051B1/hr not_active IP Right Cessation
- 2002-08-09 OA OA1200400047A patent/OA12652A/en unknown
- 2002-08-09 HU HU1900370A patent/HU231274B1/hu active Protection Beyond IP Right Term
- 2002-08-09 CN CNB028159209A patent/CN100509801C/zh not_active Expired - Lifetime
- 2002-08-09 IL IL16032802A patent/IL160328A0/xx active IP Right Grant
- 2002-08-09 MX MXPA04001401A patent/MXPA04001401A/es active IP Right Grant
- 2002-08-09 EP EP02764839A patent/EP1419152B1/en not_active Expired - Lifetime
- 2002-08-09 AU AU2002329238A patent/AU2002329238C1/en active Active
- 2002-08-09 BR BR122015023612A patent/BR122015023612B8/pt not_active IP Right Cessation
- 2002-08-09 JP JP2003521229A patent/JP2005507380A/ja not_active Withdrawn
- 2002-08-09 US US10/485,636 patent/US7125879B2/en active Active
- 2002-08-09 ES ES02764839T patent/ES2368996T3/es not_active Expired - Lifetime
- 2002-08-09 LT LTEP20165399.5T patent/LT3808743T/lt unknown
- 2002-08-09 SI SI200231101T patent/SI3808743T1/sl unknown
- 2002-08-09 KR KR1020047000372A patent/KR100817453B1/ko active IP Right Review Request
- 2002-08-09 PL PL368270A patent/PL216398B1/pl unknown
- 2002-08-09 DK DK02764839.3T patent/DK1419152T3/da active
- 2002-08-10 EG EG2002080892A patent/EG24684A/xx active
- 2002-08-12 PA PA20028552901A patent/PA8552901A1/es unknown
- 2002-08-12 AR ARP020103034A patent/AR036387A1/es active IP Right Grant
- 2002-09-08 UA UA2004031903A patent/UA78221C2/uk unknown
2004
- 2004-01-29 HR HRP20040096AA patent/HRP20040096B1/hr not_active IP Right Cessation
- 2004-02-11 IL IL160328A patent/IL160328A/en active Protection Beyond IP Right Term
- 2004-02-12 ZA ZA2004/01159A patent/ZA200401159B/en unknown
- 2004-02-12 NO NO20040633A patent/NO327639B1/no not_active IP Right Cessation
2005
- 2005-04-01 HK HK05102760.9A patent/HK1070066A1/xx not_active IP Right Cessation
2006
- 2006-06-26 US US11/474,855 patent/US8080551B2/en not_active Expired - Fee Related
2008
- 2008-09-02 NO NO20083770A patent/NO337142B1/no not_active IP Right Cessation
2009
- 2009-11-12 JP JP2009259107A patent/JP5247661B2/ja not_active Expired - Lifetime
2010
- 2010-12-21 HK HK10111939.9A patent/HK1145449A1/xx not_active IP Right Cessation
2011
- 2011-06-16 JP JP2011134088A patent/JP4838396B2/ja not_active Expired - Lifetime
- 2011-06-17 JP JP2011135468A patent/JP5539927B2/ja not_active Expired - Lifetime
- 2011-09-30 US US13/249,796 patent/US20120076835A1/en not_active Abandoned
- 2011-10-26 CY CY20111101014T patent/CY1112331T1/el unknown
2012
- 2012-03-23 HR HRP20120265A patent/HRP20120265B1/hr not_active IP Right Cessation
- 2012-05-08 BE BE2012C020C patent/BE2012C020I2/nl unknown
- 2012-05-16 LU LU92001C patent/LU92001I2/fr unknown
- 2012-05-18 CY CY2012012C patent/CY2012012I1/el unknown
- 2012-05-22 FR FR12C0035C patent/FR12C0035I2/fr active Active
- 2012-05-23 NO NO2012010C patent/NO2012010I2/no unknown
- 2012-05-24 BE BE2012C022C patent/BE2012C022I2/nl unknown
- 2012-05-24 LU LU92008C patent/LU92008I2/fr unknown
- 2012-05-25 FR FR12C0036C patent/FR12C0036I2/fr active Active
- 2012-05-25 CY CY2012013C patent/CY2012013I2/el unknown
- 2012-05-25 DE DE201212000038 patent/DE122012000038I1/de active Pending
2014
- 2014-08-05 US US14/451,761 patent/US9580392B2/en not_active Expired - Lifetime
2015
- 2015-10-20 HU HUS1500051C patent/HUS1500051I1/hu unknown
2016
- 2016-02-03 HU HUS1500055C patent/HUS1500055I1/hu unknown
2017
- 2017-01-16 US US15/406,918 patent/US20170121292A1/en not_active Abandoned
- 2017-07-20 US US15/655,570 patent/US9981919B2/en not_active Expired - Lifetime
2018
- 2018-04-26 US US15/963,352 patent/US10370340B2/en not_active Expired - Fee Related
2019
- 2019-07-02 US US16/460,898 patent/US10611732B2/en not_active Expired - Fee Related
2022
- 2022-07-27 FR FR22C1036C patent/FR22C1036I1/fr active Active
- 2022-07-28 BE BE2022C531C patent/BE2022C531I2/nl unknown
- 2022-08-01 CY CY2022024C patent/CY2022024I1/el unknown
- 2022-08-02 LT LTPA2022515C patent/LTC3808743I2/lt unknown
- 2022-08-02 HU HUS2200038C patent/HUS2200038I1/hu unknown

Also Published As

Publication number	Publication date
WO2003016306A1 (en)	2003-02-27
PL402388A1 (pl)	2013-04-02
KR100969273B1 (ko)	2010-08-20
BE2012C020I2 (el)	2021-07-19
HU230192B1 (hu)	2015-09-28
US20180244632A1 (en)	2018-08-30
US9580392B2 (en)	2017-02-28
KR100817453B1 (ko)	2008-03-27
HK1070066A1 (en)	2005-06-10
HRP20192051A2 (hr)	2020-03-06
EP3808743B1 (en)	2022-07-20
HK1145449A1 (en)	2011-04-21
FR12C0035I1 (el)	2012-06-22
HUS1500055I1 (hu)	2016-03-29
US7125879B2 (en)	2006-10-24
AU2002329238B2 (en)	2008-01-24
NO2012010I2 (no)	2013-09-02
NO20040633L (no)	2004-03-12
US9981919B2 (en)	2018-05-29
NO327639B1 (no)	2009-09-07
HRP20120265B1 (hr)	2019-11-29
JP2011225589A (ja)	2011-11-10
BR122015023612B8 (pt)	2021-05-25
SI3808743T1 (sl)	2022-09-30
DK3808743T3 (da)	2022-08-01
HUS2200038I1 (hu)	2022-08-28
FR12C0036I1 (el)	2012-06-29
CN1541215A (zh)	2004-10-27
JO3429B1 (ar)	2019-10-20
BR0211909A (pt)	2004-08-24
JP2005507380A (ja)	2005-03-17
BR122015032641B1 (pt)	2022-03-03
JP5247661B2 (ja)	2013-07-24
CY2022024I2 (el)	2023-01-05
JP2010077140A (ja)	2010-04-08
PL368270A1 (en)	2005-03-21
LT3808743T (lt)	2022-08-10
NO2012010I1 (no)	2012-06-18
OA12652A (en)	2006-06-15
US20170121292A1 (en)	2017-05-04
HRP20040096A2 (en)	2004-06-30
CY2012013I1 (el)	2015-08-05
CN101816658B (zh)	2014-08-27
ES2923581T3 (es)	2022-09-28
US20170320835A1 (en)	2017-11-09
HRP20040096B1 (hr)	2013-06-30
HUS1500051I1 (hu)	2018-05-28
AP1610A (en)	2006-05-08
JP5539927B2 (ja)	2014-07-02
NO20083770L (no)	2004-03-12
MXPA04001401A (es)	2004-05-27
DE122012000038I1 (de)	2012-09-20
EG24684A (en)	2010-05-05
EP1419152A1 (en)	2004-05-19
UA78221C2 (uk)	2007-03-15
CY2012012I2 (el)	2015-08-05
EP2298761A1 (en)	2011-03-23
NO337142B1 (no)	2016-02-01
LU92008I2 (fr)	2012-07-24
US20140343006A1 (en)	2014-11-20
CN100509801C (zh)	2009-07-08
HUP0401346A2 (hu)	2004-12-28
AU2002329238C1 (en)	2008-08-28
EP2298761B1 (en)	2020-03-25
HUP0401346A3 (en)	2009-03-02
JP4838396B2 (ja)	2011-12-14
ZA200401159B (en)	2005-07-27
FR12C0035I2 (fr)	2016-02-12
NZ530951A (en)	2005-10-28
AP2004002993A0 (en)	2004-03-31
CA2452217C (en)	2009-06-16
EP1419152B1 (en)	2011-07-27
LTC3808743I2 (el)	2023-04-25
US10611732B2 (en)	2020-04-07
LTPA2022515I1 (el)	2022-08-25
DK1419152T3 (da)	2011-10-24
BRPI0211909B8 (pt)	2021-05-25
US8080551B2 (en)	2011-12-20
ES2368996T3 (es)	2011-11-24
US20060252764A1 (en)	2006-11-09
AR036387A1 (es)	2004-09-08
MY189572A (en)	2022-02-17
CN101816658A (zh)	2010-09-01
US20190322628A1 (en)	2019-10-24
PA8552901A1 (es)	2003-02-28
BR122015023612B1 (pt)	2021-01-19
FR22C1036I1 (fr)	2022-09-09
CY1112331T1 (el)	2015-08-05
EA006656B1 (ru)	2006-02-24
LU92001I2 (fr)	2012-07-16
IL160328A0 (en)	2004-07-25
SI1419152T1 (sl)	2011-11-30
BE2022C531I2 (el)	2022-08-09
PT1419152E (pt)	2011-10-11
EA200400304A1 (ru)	2004-08-26
KR20040023645A (ko)	2004-03-18
US20120076835A1 (en)	2012-03-29
FR12C0036I2 (fr)	2016-05-06
HRP20120265A2 (hr)	2012-05-31
BRPI0211909B1 (pt)	2018-05-29
HRP20192051B1 (hr)	2022-05-27
CY2012012I1 (el)	2015-08-05
HU231274B1 (hu)	2022-07-28
JP2011236221A (ja)	2011-11-24
ATE517891T1 (de)	2011-08-15
EP3808743A1 (en)	2021-04-21
IL160328A (en)	2011-01-31
CY2012013I2 (el)	2015-08-05
ES2799408T3 (es)	2020-12-17
US20040198739A1 (en)	2004-10-07
PL216398B1 (pl)	2014-03-31
BE2012C022I2 (el)	2022-01-12
KR20070101409A (ko)	2007-10-16
CA2452217A1 (en)	2003-02-27
US10370340B2 (en)	2019-08-06

Publication	Publication Date	Title
CY2022024I1 (el)	2023-01-05	Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv
ATA5552001A (de)	2002-12-15	Verbindung von plattenförmigen bauteilen
DK1303496T3 (da)	2007-12-27	Pyrimidinderivater
NO20042742L (no)	2004-08-24	Pyrimidinforbindelser
ES1049907Y (es)	2002-06-01	Peonzas de juguete.
DE60214255D1 (de)	2006-10-12	Schlussstück
DE50202182D1 (de)	2005-03-10	Multipliziererschaltung
IS6933A (is)	2003-08-27	Veirueyðandi samsetningar
NO20032291D0 (no)	2003-05-21	Pyrimidinderivater
IS7212A (is)	2004-04-07	Veiruhindrun með n-dókósanóli
DE10296144D2 (de)	2004-10-28	Koffer
DE60217632D1 (de)	2007-03-08	Wandnachbildungen
DE60223782D1 (de)	2008-01-10	Kombination von Frontplatten
DE50200043D1 (de)	2003-10-16	Steighilfe
DE60221724D1 (de)	2007-09-27	Anti-HIV Substanz
NO20041687L (no)	2004-04-26	Sluttstykke
DE50207608D1 (de)	2006-09-07	Lenkflugkörper
UA5381S (uk)	2001-11-15	Правило усічене
NO20015554L (no)	2003-05-14	Hengeköye
FIU20000277U0 (fi)	2000-07-04	Jalasjärjestely
ITMI20010159U1 (it)	2002-09-19	Scaffale
FIU20010476U0 (fi)	2001-12-12	Kiinnityselin
ATE337640T1 (de)	2006-09-15	Differenzoszillator
FI5120U1 (fi)	2001-10-25	Palorajoitin
UA5412S (uk)	2001-11-15	Набір дорожнього посуду